Advertisement
BSX vs ISRG
Which Stock Would AI Choose? Boston Scientific (BSX) vs. Intuitive Surgical (ISRG) Stock Comparison
Key Takeaways
- BSX has underperformed sharply in 2026, pressured by slower growth in its WATCHMAN and electrophysiology (EP) businesses, guidance cuts, and a series of product recalls.
- ISRG has also fallen year to date but continues to report double-digit procedure and revenue growth, keeping its operating fundamentals largely intact.
- Both stocks are medical-technology leaders, yet they differ in market positioning: BSX spans diversified interventional specialties, while ISRG dominates robotic-assisted surgery.
- ISRG trades at a premium valuation, while BSX screens as comparatively discounted after its decline.
- Relative performance and market sentiment currently diverge, with ISRG showing more stable operational momentum and BSX facing near-term execution headwinds.
Introduction
Investors evaluating large-cap medical technology often weigh diversified device franchises against focused, high-growth innovators. This stock comparison examines BSX (Boston Scientific) and ISRG (Intuitive Surgical), two healthcare names with very different growth profiles and risk exposures. Despite operating in adjacent parts of the medtech sector, the two have diverged meaningfully in recent market activity, making their relative performance a useful case study. Traders seeking momentum, long-term investors evaluating market positioning, and those comparing valuation with growth durability may all find this comparison relevant. The analysis focuses on recent business developments, sentiment shifts, and observable trend signals rather than short-term price noise.
BSX Overview and Recent Performance
Boston Scientific develops and markets medical devices across interventional cardiology, cardiac rhythm management, electrophysiology, endoscopy, urology, and neuromodulation. In recent weeks, BSX has traded well below its prior-year highs, with year-to-date declines of roughly 50% or more reflecting a sustained de-rating rather than an isolated event.
Several factors have weighed on sentiment. Management has reduced full-year 2026 guidance multiple times, citing slower U.S. growth in WATCHMAN (a left atrial appendage closure device) and competitive share erosion in electrophysiology. A cybersecurity incident, a worldwide Class I recall of certain angiographic catheters, and additional recall activity have compounded regulatory and operational concerns. The company has also pursued significant strategic moves, including a planned acquisition of Penumbra and a restructuring program targeting meaningful run-rate savings, alongside a substantial accelerated share repurchase. These actions signal management's focus on margins and capital deployment, but near-term execution risk and integration uncertainty have kept BSX under pressure.
ISRG Overview and Recent Performance
Intuitive Surgical is the pioneer and dominant player in robotic-assisted surgery, best known for its da Vinci systems and the Ion endoluminal platform. In recent market activity, ISRG has declined meaningfully from its early-2026 peak, yet its underlying operating performance has remained comparatively strong. Recent quarters showed revenue growth near 20%, double-digit procedure growth, and an expanding installed base, driven in part by adoption of the newer da Vinci 5 platform.
Sentiment has been pressured by concerns outside the core business: increased competition in China from domestic robotic manufacturers, the effect of GLP-1 weight-loss drugs on U.S. bariatric procedure volumes, and emerging rivals such as Johnson & Johnson's OTTAVA system. Still, recurring revenue represents the large majority of ISRG sales, providing a stable, high-margin base. The stock's premium valuation has compressed relative to historical levels, though it remains elevated compared with more diversified device peers. The tension between durable growth and a rich multiple continues to define the stock's positioning.
Trending AI Robots
Tickeron operates a broad marketplace of AI trading bots, with hundreds of automated strategies that trade thousands of different tickers across varying timeframes and market conditions. Because not every bot suits every environment, only the strongest and most relevant strategies are curated into the Trending AI Robots section. Each bot carries its own trading style, strategy, timeframe, performance history, and basket of tickers, giving traders a way to compare data-driven signals rather than relying on intuition alone. These bots are designed to respond to shifting volatility, trend strength, and momentum, offering a systematic complement to manual research on names such as BSX and ISRG. Explore the Trending AI Robots page to review the strategies currently best suited to prevailing market conditions.
Head-to-Head Comparison
The two companies diverge most clearly on business model and growth drivers. BSX operates a diversified portfolio across numerous interventional specialties, giving it breadth but exposing it to product-specific slowdowns and competitive pressure in individual segments. ISRG, by contrast, is more concentrated, with a dominant installed base and a recurring, high-margin instrument and service revenue stream that underpins its profitability.
On recent momentum, ISRG holds the clearer operational edge, sustaining double-digit procedure and revenue growth despite its share-price decline. BSX faces more concrete near-term headwinds, including guidance reductions, recall activity, and integration work around major acquisitions. Risk profiles differ accordingly: BSX carries execution and regulatory risk, while ISRG carries valuation risk and competitive threats in international markets.
Sector exposure also varies. Both are healthcare names sensitive to hospital capital budgets and procedure volumes, but ISRG is more exposed to surgical procedure trends and capital-equipment cycles, while BSX is more tied to recurring device utilization across cardiology and other specialties. Market sentiment reflects these contrasts: analysts generally retain constructive ratings on both, but the market has priced BSX at a comparatively lower valuation, implying greater skepticism about a near-term recovery.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely lean toward ISRG in the current environment, primarily because of its more consistent operating trend and stable growth momentum. While ISRG carries a premium valuation and faces competitive risks, its recurring revenue base and expanding procedure volumes provide more reliable forward catalysts. BSX, by contrast, presents a potentially deeper value proposition but remains burdened by guidance cuts, recall overhangs, and acquisition integration uncertainty. In probabilistic terms, the AI would favor ISRG for trend consistency and stability, while acknowledging that BSX may offer a higher-reward, higher-uncertainty profile if its operational headwinds resolve.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BSX is a Hold and ISRG is a Hold.
BSX's Indicator enters downward trend
The Aroon Indicator for BSX entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 126 similar instances where the Aroon Indicator formed such a pattern. In 88 of the 126 cases the stock moved lower. This puts the odds of a downward move at 70%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 67 cases where BSX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 49%.
The Momentum Indicator moved below the 0 level on October 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BSX as a result. In 50 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 56%.
The Moving Average Convergence Divergence Histogram (MACD) for BSX turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 27 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.
BSX moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
BSX broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BSX's RSI Oscillator exited the oversold zone, 15 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 56%.
Following a +2.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 199 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.576) is normal, around the industry mean (4.204). P/E Ratio (17.799) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
ISRG sees MACD Histogram crosses below signal line
ISRG saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 30, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 33 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 77%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ISRG moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 17 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 46%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 61 cases where ISRG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 61%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
ISRG broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ISRG as a result. In 57 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
Following a +5.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in 210 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 183 of 264 cases where ISRG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. ISRG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 74 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.495) is normal, around the industry mean (4.877). P/E Ratio (49.420) is within average values for comparable stocks, (37.682). Projected Growth (PEG Ratio) (1.931) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
BSX | ISRG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 84 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 97 | 74 | |
SMR RATING 1..100 | 55 | 51 | |
PRICE GROWTH RATING 1..100 | 64 | 47 | |
P/E GROWTH RATING 1..100 | 95 | 80 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BSX's Valuation (68) in the Medical Specialties industry is in the same range as ISRG (78). This means that BSX’s stock grew similarly to ISRG’s over the last 12 months.
ISRG's Profit vs Risk Rating (74) in the Medical Specialties industry is in the same range as BSX (97). This means that ISRG’s stock grew similarly to BSX’s over the last 12 months.
ISRG's SMR Rating (51) in the Medical Specialties industry is in the same range as BSX (55). This means that ISRG’s stock grew similarly to BSX’s over the last 12 months.
ISRG's Price Growth Rating (47) in the Medical Specialties industry is in the same range as BSX (64). This means that ISRG’s stock grew similarly to BSX’s over the last 12 months.
ISRG's P/E Growth Rating (80) in the Medical Specialties industry is in the same range as BSX (95). This means that ISRG’s stock grew similarly to BSX’s over the last 12 months.
| BSX | ISRG | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 56% | 2 days ago 46% |
| Stochastic ODDS (%) | 2 days ago 49% | 2 days ago 61% |
| Momentum ODDS (%) | 2 days ago 56% | 2 days ago 73% |
| MACD ODDS (%) | 2 days ago 60% | 2 days ago 77% |
| TrendWeek ODDS (%) | 2 days ago 55% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 66% |
| Advances ODDS (%) | 15 days ago 59% | 12 days ago 66% |
| Declines ODDS (%) | 7 days ago 54% | 7 days ago 61% |
| BollingerBands ODDS (%) | 2 days ago 55% | 2 days ago 47% |
| Aroon ODDS (%) | 2 days ago 70% | 2 days ago 69% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BSX’s FA Score shows that 0 FA rating(s) are green while ISRG’s FA Score has 0 green FA rating(s).
- BSX’s FA Score: 0 green, 5 red.
- ISRG’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BSX’s TA Score shows that 2 TA indicator(s) are bullish while ISRG’s TA Score has 3 bullish TA indicator(s).
- BSX’s TA Score: 2 bullish, 7 bearish.
- ISRG’s TA Score: 3 bullish, 5 bearish.
Price Growth
BSX (@Medical/Nursing Services) experienced а -2.76% price change this week, while ISRG (@Pharmaceuticals: Other) price change was -3.27% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.01%. For the same industry, the average monthly price growth was -6.09%, and the average quarterly price growth was -8.21%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.56%. For the same industry, the average monthly price growth was -1.59%, and the average quarterly price growth was +10.19%.
Reported Earning Dates
BSX is expected to report earnings on Feb 03, 2027.
ISRG is expected to report earnings on Jan 26, 2027.
Industries' Descriptions
@Medical/Nursing Services (+0.01% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (-0.56% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
ISRG and
Correlation & Price change
A.I.dvisor indicates that over the last year, ISRG has been closely correlated with BSX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if ISRG jumps, then BSX could also see price increases.
| Ticker / NAME | Correlation To ISRG | 1D Price Change % | ||
|---|---|---|---|---|
| ISRG | 100% | +1.12% | ||
| BSX - ISRG | 73% Closely correlated | +5.57% | ||
| SYK - ISRG | 64% Loosely correlated | +5.12% | ||
| NTRA - ISRG | 54% Loosely correlated | -8.54% | ||
| GKOS - ISRG | 51% Loosely correlated | +0.43% | ||
| PODD - ISRG | 49% Loosely correlated | +2.63% | ||
More | ||||